News

41. Quanticate Expands Operations In India And Its Commitment To Provide High Quality, Effective Data-Related CRO Services To Support Clinical Trials 5/10/2012

    Quanticate, a leading global data-focused clinical research organization (CRO), today announced expansion of its capabilities in India with the opening of a new office in Bangalore, India.

42. Rexahn Pharmaceuticals Submits Archexin Phase II Protocol For Ovarian Cancer To FDA 5/8/2012

    Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, recently announced that it has submitted a Phase II protocol for the clinical study of Archexin as a treatment of ovarian cancer to the U.S. Food and Drug Administration (FDA).

43. XARELTO (rivaroxaban) Demonstrates Comparable Efficacy To Standard Of Care For The Treatment And Secondary Prevention Of Venous Blood Clots In Patients With Symptomatic Pulmonary Embolism In Pivotal Phase 3 Study 3/27/2012
    Janssen Research & Development, LLC, (Janssen), announced results of the EINSTEIN-PE study showing that the oral anticoagulant XARELTO (rivaroxaban) was comparable to today’s standard of care in treating patients with acute symptomatic pulmonary embolism (PE) and in preventing development of a secondary venous blood clot (known as venous thromboembolism or VTE).
44. Ampio Announces Positive Preliminary Update On The Optina™ Clinical Trial To Treat Diabetic Macular Edema And Decision To Conclude The Study Ahead Of Schedule 3/20/2012
    Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Zertane™ completed two phase III studies, Ampion™-completed proof of concept studies and Optina™), licensing distribution of these drugs and engaged in further drug development, today announced that it completed the planned interim review of the first 50% of patients enrolled in the Optina™ trial for diabetic macular edema.
45. Celerion And Ricerca Biosciences Announce 'The Biosimilars Alliance' To Offer Clients A More Effective Development Path For Biosimilars 3/1/2012

    Celerion, the premier provider of innovative early stage drug development solutions, and Ricerca Biosciences, a drug safety assessment expert in harnessing external preclinical innovation, announce the formation of “The Biosimilars Alliance”.

46. Premier Research Expands Salt Lake City And Phoenix Testing Facilities Adding 50% Capacity 2/22/2012
    Premier Research Group Limited announces the opening of new state-of-the-art clinical research facilities located in Phoenix and Salt Lake City, increasing their testing facilities capacity by 50%.
47. BrainStorm Announces Clinical Data For Safety And Supporting Efficacy Of NurOwn™ Based On Initial Phase I/II Results 1/18/2012
    BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), an innovative developer of adult stem cell technologies and Central Nervous System (CNS) therapeutics, recently announced that the data from the initial patients in its ALS Phase I/II human clinical trial treated with its NurOwn™ technology did not present any significant side effects and that the NurOwn™ treatment has so far proven to be safe.
48. Premier Research Names Dr. Colin Hayward As European Medical Director 1/18/2012
    Premier Research Group announces the appointment of Dr. Colin Hayward to the position of European Medical Director. In this position, Dr. Hayward will be responsible for leading and developing the company’s European medical affairs and pharmacovigilance operations, critical components of the company’s global clinical development services offered to the biopharmaceutical industry.
49. Oxygen Biotherapeutics To Begin Clinical Study To Determine Efficacy Of Dermacyte® In Relieving Histamine Induced Pruritus 1/10/2012
    Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX Swiss Exchange:OXBT) announced today that enrollment for the company's first dermatological study will begin later this month at St. John's Medical College Hospital in Bangalore, India.
50. Sitrof Technologies Introduces Argus Capture For Unstructured Content Management 12/28/2011

    Sitrof Technologies, a leading provider of unstructured content management solutions for the life sciences industry, announced a new product recently, Sitrof Argus Capture powered by EMC InputAccel.